Review



snp microarray data  (Partners HealthCare System Inc)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Partners HealthCare System Inc snp microarray data
    Summary of major studies associating L-CH with lymphoid malignancy.
    Snp Microarray Data, supplied by Partners HealthCare System Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/snp+microarray+data/snp+microarray+data/pmc09813350-12-57-70
    Average 90 stars, based on 1 article reviews
    snp microarray data - by Bioz Stars, 2026-11
    90/100 stars

    Images

    1) Product Images from "Lymphoid clonal hematopoiesis: implications for malignancy, immunity, and treatment"

    Article Title: Lymphoid clonal hematopoiesis: implications for malignancy, immunity, and treatment

    Journal: Blood Cancer Journal

    doi: 10.1038/s41408-022-00773-8

    Summary of major studies associating L-CH with lymphoid malignancy.
    Figure Legend Snippet: Summary of major studies associating L-CH with lymphoid malignancy.

    Techniques Used: Genome Wide, Sequencing, Mutagenesis, Clone Assay, Biomarker Discovery, Microarray, DNA Sequencing, Clinical Proteomics

    Related Articles

    Biomarker Discovery:

    Article Title: Lymphoid clonal hematopoiesis: implications for malignancy, immunity, and treatment
    Article Snippet: Terao et al. (2020) , Detection of mCAs in blood from one or more Infinium Human SNP Arrays , 179,417 individuals from the Biobank Japan cohort , Common mutational precursors of CLL (trisomy 12, 13q deletion, and 13q LOH) were less frequent in Japanese individuals compared to the UK Biobank cohort. Selective pressure for specific mCAs varies with genetic background, consistent with the lower rates of CLL and higher rates of T-cell leukemia in the Japanese. , [ ] . .. Niroula et al. (2021) , Detection of SNVs/indels in WES data at 56 M-CH related genes and 235 genes recurrently mutated in lymphoid malignancy (VAF > 2%). mCAs were previously detected in a prior study. CH and mCAs were excluded if they were detected less than 6 months before a hematologic malignancy diagnosis. , 420,969 individuals with SNP microarray data and 55,383 individuals with WES from the UK Biobank and Mass General Brigham Biobank , CHIP occurs at both M-CHIP/M-mCA and L-CHIP/L-mCA loci and increases with age. M-CH and L-CH loci clearly segregate on the incidence myeloid and lymphoid malignancy. M-CHIP is dominated by DNMT3A, TET2, and ASXL1 somatic mutants, while L-CHIP is spread more evenly across a large number of genes. CLL was the dominant lymphoid malignancy occurring subsequent to L-CH. , [ ] . .. Saiki et al. (2021) , Detection of SNVs/indels by targeted sequencing of 23 CH-associated genes (predominantly M-CH, VAF > 0.5%) and detection of CNAs by one of three Illumina array types , 11,234 individuals without hematologic malignancy from the Biobank Japan cohort , Detection of CH strongly correlated with subsequent death attributable to myeloid malignancy (160/215) but only weakly with lymphoid malignancy (191/420) compared to non-hematologic malignancy death controls (4,209/10,562). These observations held true for all myeloid malignancy subtypes and lymphoid malignancy subtypes except CLL (7/7) and ALL (7/12). , [ ] .

    Microarray:

    Article Title: Lymphoid clonal hematopoiesis: implications for malignancy, immunity, and treatment
    Article Snippet: Terao et al. (2020) , Detection of mCAs in blood from one or more Infinium Human SNP Arrays , 179,417 individuals from the Biobank Japan cohort , Common mutational precursors of CLL (trisomy 12, 13q deletion, and 13q LOH) were less frequent in Japanese individuals compared to the UK Biobank cohort. Selective pressure for specific mCAs varies with genetic background, consistent with the lower rates of CLL and higher rates of T-cell leukemia in the Japanese. , [ ] . .. Niroula et al. (2021) , Detection of SNVs/indels in WES data at 56 M-CH related genes and 235 genes recurrently mutated in lymphoid malignancy (VAF > 2%). mCAs were previously detected in a prior study. CH and mCAs were excluded if they were detected less than 6 months before a hematologic malignancy diagnosis. , 420,969 individuals with SNP microarray data and 55,383 individuals with WES from the UK Biobank and Mass General Brigham Biobank , CHIP occurs at both M-CHIP/M-mCA and L-CHIP/L-mCA loci and increases with age. M-CH and L-CH loci clearly segregate on the incidence myeloid and lymphoid malignancy. M-CHIP is dominated by DNMT3A, TET2, and ASXL1 somatic mutants, while L-CHIP is spread more evenly across a large number of genes. CLL was the dominant lymphoid malignancy occurring subsequent to L-CH. , [ ] . .. Saiki et al. (2021) , Detection of SNVs/indels by targeted sequencing of 23 CH-associated genes (predominantly M-CH, VAF > 0.5%) and detection of CNAs by one of three Illumina array types , 11,234 individuals without hematologic malignancy from the Biobank Japan cohort , Detection of CH strongly correlated with subsequent death attributable to myeloid malignancy (160/215) but only weakly with lymphoid malignancy (191/420) compared to non-hematologic malignancy death controls (4,209/10,562). These observations held true for all myeloid malignancy subtypes and lymphoid malignancy subtypes except CLL (7/7) and ALL (7/12). , [ ] .



    Similar Products

    snp microarray data  (Jingxin Pharmaceutical Co Ltd)
    86
    Jingxin Pharmaceutical Co Ltd snp microarray data
    Snp Microarray Data, supplied by Jingxin Pharmaceutical Co Ltd, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/snp+microarray+data/data+microarray+snp/pm41548397-144-22-18
    Average 86 stars, based on 1 article reviews
    snp microarray data - by Bioz Stars, 2026-11
    86/100 stars
    		  Buy from Supplier
    microarray snp genotype data  (Illumina Inc)
    90
    Illumina Inc microarray snp genotype data
    Microarray Snp Genotype Data, supplied by Illumina Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/snp+microarray+data/snp+genotypes/pm40563917-118-13-18
    Average 90 stars, based on 1 article reviews
    microarray snp genotype data - by Bioz Stars, 2026-11
    90/100 stars
    		  Buy from Supplier
    immunochip microarray snp data  (Illumina Inc)
    90
    Illumina Inc immunochip microarray snp data
    Immunochip Microarray Snp Data, supplied by Illumina Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/snp+microarray+data/illumina+immunochip/pmc09893534__13040_2023_321_MOESM1_ESM-20-2-12
    Average 90 stars, based on 1 article reviews
    immunochip microarray snp data - by Bioz Stars, 2026-11
    90/100 stars
    		  Buy from Supplier
    snp microarray data  (Partners HealthCare System Inc)
    90
    Partners HealthCare System Inc snp microarray data
    Summary of major studies associating L-CH with lymphoid malignancy.
    Snp Microarray Data, supplied by Partners HealthCare System Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/snp+microarray+data/snp+microarray+data/pmc09813350-12-57-70
    Average 90 stars, based on 1 article reviews
    snp microarray data - by Bioz Stars, 2026-11
    90/100 stars
    		  Buy from Supplier
    snp 6.0 microarray data  (Thermo Fisher)
    90
    Thermo Fisher snp 6.0 microarray data
    Summary of major studies associating L-CH with lymphoid malignancy.
    Snp 6.0 Microarray Data, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/snp+microarray+data/pmc08908645-46-2-1
    Average 90 stars, based on 1 article reviews
    snp 6.0 microarray data - by Bioz Stars, 2026-11
    90/100 stars
    		  Buy from Supplier
    snp 6 0 microarray data  (Thermo Fisher)
    86
    Thermo Fisher snp 6 0 microarray data
    Summary of major studies associating L-CH with lymphoid malignancy.
    Snp 6 0 Microarray Data, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/snp+microarray+data/pm32759987-52-2-1
    Average 86 stars, based on 1 article reviews
    snp 6 0 microarray data - by Bioz Stars, 2026-11
    86/100 stars
    		  Buy from Supplier

    Image Search Results


    Summary of major studies associating L-CH with lymphoid malignancy.

    Journal: Blood Cancer Journal

    Article Title: Lymphoid clonal hematopoiesis: implications for malignancy, immunity, and treatment

    doi: 10.1038/s41408-022-00773-8

    Figure Lengend Snippet: Summary of major studies associating L-CH with lymphoid malignancy.

    Article Snippet: Niroula et al. (2021) , Detection of SNVs/indels in WES data at 56 M-CH related genes and 235 genes recurrently mutated in lymphoid malignancy (VAF > 2%). mCAs were previously detected in a prior study. CH and mCAs were excluded if they were detected less than 6 months before a hematologic malignancy diagnosis. , 420,969 individuals with SNP microarray data and 55,383 individuals with WES from the UK Biobank and Mass General Brigham Biobank , CHIP occurs at both M-CHIP/M-mCA and L-CHIP/L-mCA loci and increases with age. M-CH and L-CH loci clearly segregate on the incidence myeloid and lymphoid malignancy. M-CHIP is dominated by DNMT3A, TET2, and ASXL1 somatic mutants, while L-CHIP is spread more evenly across a large number of genes. CLL was the dominant lymphoid malignancy occurring subsequent to L-CH. , [ ] .

    Techniques: Genome Wide, Sequencing, Mutagenesis, Clone Assay, Biomarker Discovery, Microarray, DNA Sequencing, Clinical Proteomics